Oxacillin Treatment of Severe Staphylococcal Infections

Abstract

OXACILLIN (5-methyl-3-phenyl-4-isoxazolyl penicillin) is a new semisynthetic penicillin¹ that has been demonstrated to be resistant to penicillinase^{2 3 4} and to possess the following readily recognized advantages over methicillin: acid stability, which permits absorption after oral administration, in contrast to the acid lability of methicillin, which is essentially unabsorbed when given orally^{1 , 2}; greater activity in vitro against staphylococci,^{2 , 5 6 7 8 9 10 11} both those resistant to penicillin G that produce penicillinase and sensitive, nonpenicillinase producers; and greater activity against other susceptible gram-positive cocci.^{2 , 5 , 7 , 10} The present report is an analysis of the results of treatment with oxacillin of 124 patients with serious staphylococcal disease at the . . .